Hims & Hers Health, Inc. (HIMS)
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides
Hims & Hers Health's plan to enter the business of selling peptides is looking a lot more realistic.
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.
Hims & Hers Advances a Consumer-Centric Digital Health Platform
HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Telehealth giant Hims & Hers says its customer support system was hacked
Hims & Hers, the telehealth company that sells weight-loss drugs and sexual health prescriptions, has confirmed a data breach affecting its third-party customer service platform.
Hims & Hers Expands Personalized Digital Healthcare Platform
HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.
Hims & Hers Health, Inc. (HIMS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.78, denoting a -3.1% move from the preceding trading day.
Hims & Hers: The Reset Before The Next Inflection
Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M shares (~40% float), while days-to-cover expanded from ~1.0 to ~3.6. Short volume intensity declined from ~62–64% during the selloff to ~45%, signaling reduced marginal short pressure.
Hims & Hers: Distressed Valuations Will Not Last For Long
Hims resolved its legal dispute with Novo Nordisk, removing a major overhang and enabling it to offer branded drugs. Valuations have not recovered to pre-lawsuit levels as persistent insider selling and changes in disclosure have weighed negatively on sentiment. Consensus underestimates the inherent story in Hims emanating from growth in subscribers, sustainability and penetration in new products & markets.
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
